Steven L Barriere
Overview
Explore the profile of Steven L Barriere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Samara E, Shaw J, Barriere S, Wong S, Worboys P
Antimicrob Agents Chemother
. 2012 Jan;
56(4):2067-73.
PMID: 22252798
A population pharmacokinetic model of telavancin, a lipoglycopeptide antibiotic, was developed and used to identify sources of interindividual variability. Data were obtained from healthy subjects (seven phase 1 studies), patients...
22.
Sharma-Kuinkel B, Ahn S, Rude T, Zhang Y, Tong S, Ruffin F, et al.
J Clin Microbiol
. 2011 Dec;
50(3):848-56.
PMID: 22205797
The impact of Panton-Valentine leukocidin (PVL) on the outcome in Staphylococcus aureus pneumonia is controversial. We genotyped S. aureus isolates from patients with hospital-acquired pneumonia (HAP) enrolled in two registrational...
23.
Rubinstein E, Lalani T, Corey G, Kanafani Z, Nannini E, Rocha M, et al.
Clin Infect Dis
. 2010 Dec;
52(1):31-40.
PMID: 21148517
Background: Telavancin is a lipoglycopeptide bactericidal against gram-positive pathogens. Methods: Two methodologically identical, double-blind studies (0015 and 0019) were conducted involving patients with hospital-acquired pneumonia (HAP) due to gram-positive pathogens,...
24.
Barriere S
Future Microbiol
. 2010 Nov;
5(12):1765-73.
PMID: 21080861
Telavancin is an injectable lipoglycopeptide that is bactericidal in vitro against staphylococci, streptococci and vancomycin-susceptible enterococci. Telavancin inhibits bacterial cell wall synthesis by interfering with the synthesis of peptidoglycan, and...
25.
Krause K, Barriere S, Kitt M, Benton B
Diagn Microbiol Infect Dis
. 2010 Sep;
68(2):181-5.
PMID: 20846593
During phase 3 clinical studies of telavancin for treatment of complicated skin and skin structure infections, a total of 1530 aerobic Gram-positive isolates were identified at baseline. The majority of...
26.
Goldberg M, Wong S, Shaw J, Kitt M, Barriere S
Pharmacotherapy
. 2010 Jul;
30(8):806-11.
PMID: 20653356
Study Objective: To assess the safety and tolerability, and the effect of sex on the pharmacokinetic disposition, of a single intravenous dose of telavancin 10 mg/kg in elderly (> or...
27.
Barriere S
Clin Infect Dis
. 2010 Jul;
51 Suppl 1:S4-9.
PMID: 20597670
Hospital-acquired pneumonia and ventilator-associated pneumonia are associated with high rates of morbidity and mortality and are often caused by drug-resistant pathogens. Trials of potential new agents to treat these serious...
28.
Wong S, Goldberg M, Ballow C, Kitt M, Barriere S
Pharmacotherapy
. 2010 Jan;
30(2):136-43.
PMID: 20099988
Study Objective: To examine the effect of telavancin, a lipoglycopeptide antibiotic with potent gram-positive activity, on the pharmacokinetics of midazolam, a cytochrome P450 (CYP) 3A probe substrate. Design. Phase I,...
29.
Goldberg M, Wong S, Shaw J, Kitt M, Barriere S
Pharmacotherapy
. 2009 Dec;
30(1):35-42.
PMID: 20030471
Study Objective: To evaluate the pharmacokinetics of the lipoglycopeptide antibiotic, telavancin, in patients with moderate hepatic impairment compared with healthy controls. Design: Phase I, open-label, single-dose, matched-control, pilot study. Setting:...
30.
Patel J, Churchwell M, Seroogy J, Barriere S, Grio M, Mueller B
Int J Artif Organs
. 2009 Nov;
32(10):745-51.
PMID: 19943236
Background/aims: Telavancin is a lipoglycopeptide antimicrobial agent which has been approved in Europe and has been recently FDA approved in the United States. Telavancin's parenteral solution contains hydroxy propyl-beta -cyclodextrin...